These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20359717)

  • 1. Re: Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. B. J. Trock, C. C. Guo, M. L. Gonzalgo, A. Magheli, S. Loeb and J. I. Epstein. J Urol 2009; 182: 1364-1370.
    Ikenberg K; Zimmermann AK; Kristiansen G
    J Urol; 2010 May; 183(5):2100; author reply 2100-1. PubMed ID: 20359717
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
    Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
    J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy: C. Von Bodman, G. Godoy, D. C. Chade, A. Cronin, L. J. Tafe, S. W. Fine, V. Laudone, P. T. Scardino and J. A. Eastham J Urol 2010; 184: 143-148.
    Cai T; Nesi G; Malossini G; Bartoletti R
    J Urol; 2011 Jan; 185(1):360-1; author reply 361. PubMed ID: 21092995
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    McDonald MW
    J Urol; 1998 Oct; 160(4):1442. PubMed ID: 9751386
    [No Abstract]   [Full Text] [Related]  

  • 8. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
    J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.
    Gonzalgo ML; Bastian PJ; Mangold LA; Trock BJ; Epstein JI; Walsh PC; Partin AW
    Urology; 2006 Jan; 67(1):115-9. PubMed ID: 16413345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories: E. A. Klein, F. J. Bianco, A. M. Serio, J. A. Eastham, M. W. Kattan, J. E. Pontes, A. J. Vickers and P. T. Scardino J Urol 2008; 179: 2212-2217.
    Sivanandam A; Bhandari M
    J Urol; 2008 Dec; 180(6):2716-7; author reply 2717-8. PubMed ID: 18951589
    [No Abstract]   [Full Text] [Related]  

  • 14. Interval from prostate biopsy to radical prostatectomy: effect on PSA, Gleason sum, and risk of recurrence.
    Shibata A; Mohanasundaram UM; Terris MK
    Urology; 2005 Oct; 66(4):808-13. PubMed ID: 16230143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
    J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.